NEUP
Neuphoria Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$23M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisNEUP
ALKS
ACAD
INVA
Try popular comparisons:
Stock Comparison
NEUP vs ALKS vs ACAD vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
ALKS
Alkermes plc
Biotechnology
Market Cap$7.50B
5Y Perf.+93.4%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.70B
5Y Perf.-7.4%
INVA
Innoviva, Inc.
Biotechnology
Market Cap$1.66B
5Y Perf.+30.4%
NEUP vs ALKS vs ACAD vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NEUP |  ALKS |  ACAD |  INVA |
|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $23M | $7.50B | $3.70B | $1.66B |
| Revenue (TTM) | $-10M | $1.56B | $1.10B | $424M |
| Net Income (TTM) | $-28M | $153M | $376M | $504M |
| Gross Margin | 100.0% | 65.4% | 91.5% | 76.2% |
| Operating Margin | -7.2% | 12.3% | 7.4% | 14.8% |
| Forward P/E | — | 31.5x | 55.6x | 6.3x |
| Total Debt | $226K | $70M | $52M | $269M |
| Cash & Equiv. | $22M | $1.12B | $178M | $551M |
NEUP vs ALKS vs ACAD vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NEUP
ALKS
ACAD
INVA
| Stock | Dec 21 | Jun 26 | Return |
|---|---|---|---|
| Neuphoria Therapeut… (NEUP) | 100 | 2.9 | -97.1% |
| Alkermes plc (ALKS) | 100 | 193.4 | +93.4% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 92.6 | -7.4% |
| Innoviva, Inc. (INVA) | 100 | 130.4 | +30.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEUP vs ALKS vs ACAD vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INVA leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Alkermes plc is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇INVA emerged as the overall leader. Track its performance:
NEUP
Neuphoria Therapeutics Inc.
The Quality Angle
NEUP plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ALKS
Alkermes plc
The Momentum Pick
ALKS is the #2 pick in this set and the best alternative if momentum is your priority.
- +53.4% vs NEUP's -34.9%
Best for: momentum
ACAD
ACADIA Pharmaceuticals Inc.
The Secondary Option
ACAD lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
INVA
Innoviva, Inc.
The Income Pick
INVA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 2 yrs, beta 0.03
- Rev growth 18.5%, EPS growth 8.2%, 3Y rev CAGR 8.7%
- 101.2% 10Y total return vs ALKS's 7.4%
- Lower volatility, beta 0.03, Low D/E 22.9%, current ratio 14.64x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  INVA | 18.5% revenue growth vs NEUP's -140.1% |
| Value | INVA | Lower P/E (6.3x vs 55.6x) |
| Quality / Margins | INVA | 118.9% margin vs NEUP's -2.4% |
| Stability / Safety | INVA | Beta 0.03 vs NEUP's 1.38 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  ALKS | +53.4% vs NEUP's -34.9% |
| Efficiency (ROA) | INVA | 32.4% ROA vs NEUP's -77.5%, ROIC 14.2% vs -13.4% |
NEUP vs ALKS vs ACAD vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2018
FY 2025
NEUP vs ALKS vs ACAD vs INVA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINVALAGGINGACAD
Who Leads Where
INVA leads in 2 of 6 categories
NEUP leads 1 • ALKS leads 0 • ACAD leads 0 • 3 tied
Explore the data ↓ACADACADIA Pharmaceutical…
0leads
ALKSAlkermes plc
0leads
NEUPNeuphoria Therapeutic…
1leads
INVAInnoviva, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs NEUPvs ALKSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INVA3/6
Valuation MetricsMultiples, price ratios, and targets
NEUP4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
INVA1/1
Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and NEUP operate at a comparable scale, with $1.6B and -$10M in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to NEUP's -2.4%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc |  ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | -$10M | $1.6B | $1.1B | $424M |
| EBITDAEarnings before interest/tax | -$25M | $212M | $96M | $86M |
| Net IncomeAfter-tax profit | -$28M | $153M | $376M | $504M |
| Free Cash FlowCash after capex | $59M | $392M | $212M | $181M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +65.4% | +91.5% | +76.2% |
| Operating MarginEBIT ÷ Revenue | -7.2% | +12.3% | +7.4% | +14.8% |
| Net MarginNet income ÷ Revenue | -2.4% | +9.8% | +34.3% | +118.9% |
| FCF MarginFCF ÷ Revenue | +4.9% | +25.1% | +19.4% | +42.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +28.2% | +9.7% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -101.4% | -4.1% | -81.8% | +4.0% |
INVA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
NEUP leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 6.8x trailing earnings, INVA trades at a 78% valuation discount to ALKS's 31.5x P/E. On an enterprise value basis, INVA's 6.8x EV/EBITDA is more attractive than ACAD's 25.7x.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $23M | $7.5B | $3.7B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $2M | $6.4B | $3.6B | $1.4B |
| Trailing P/EPrice ÷ TTM EPS | -18.74x | 31.46x | 9.44x | 6.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 55.56x | 6.29x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.66x |
| EV / EBITDAEnterprise value multiple | — | 22.94x | 25.75x | 6.76x |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 5.08x | 3.45x | 3.90x |
| Price / BookPrice ÷ Book value/share | 0.24x | 4.17x | 3.02x | 1.63x |
| Price / FCFMarket cap ÷ FCF | 0.30x | 15.61x | 35.20x | 8.48x |
NEUP leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — NEUP and ALKS and INVA each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 47.6% return on equity — every $100 of shareholder capital generates $48 in annual profit, vs $-110 for NEUP. NEUP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to INVA's 0.23x. On the Piotroski fundamental quality scale (0–9), NEUP scores 8/9 vs INVA's 5/9, reflecting strong financial health.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -109.7% | +8.8% | +35.6% | +47.6% |
| ROA (TTM)Return on assets | -77.5% | +5.4% | +26.2% | +32.4% |
| ROICReturn on invested capital | -13.4% | +18.9% | +10.0% | +14.2% |
| ROCEReturn on capital employed | -3.7% | +14.2% | +10.1% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.04x | 0.04x | 0.23x |
| Net DebtTotal debt minus cash | -$21M | -$1.0B | -$126M | -$282M |
| Cash & Equiv.Liquid assets | $22M | $1.1B | $178M | $551M |
| Total DebtShort + long-term debt | $226,487 | $70M | $52M | $269M |
| Interest CoverageEBIT ÷ Interest expense | — | 32.30x | — | 63.45x |
Evenly matched — NEUP and ALKS and INVA each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ALKS and INVA each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $18,423 today (with dividends reinvested), compared to $244 for NEUP. Over the past 12 months, ALKS leads with a +53.4% total return vs NEUP's -34.9%. The 3-year compound annual growth rate (CAGR) favors INVA at 20.6% vs NEUP's -47.9% — a key indicator of consistent wealth creation.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +12.8% | +59.2% | -17.3% | +13.2% |
| 1-Year ReturnPast 12 months | -34.9% | +53.4% | -5.8% | +4.8% |
| 3-Year ReturnCumulative with dividends | -85.8% | +38.7% | -9.3% | +75.4% |
| 5-Year ReturnCumulative with dividends | -97.6% | +84.2% | -16.9% | +68.7% |
| 10-Year ReturnCumulative with dividends | -97.6% | +7.4% | -42.2% | +101.2% |
| CAGR (3Y)Annualised 3-year return | -47.9% | +11.5% | -3.2% | +20.6% |
Evenly matched — ALKS and INVA each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than NEUP's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 98.3% from its 52-week high vs NEUP's 20.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 0.88x | 1.08x | 0.03x |
| 52-Week HighHighest price in past year | $21.40 | $45.76 | $27.81 | $25.15 |
| 52-Week LowLowest price in past year | $3.65 | $25.17 | $19.69 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +20.1% | +98.3% | +77.7% | +89.4% |
| RSI (14)Momentum oscillator 0–100 | 36.3 | 69.5 | 51.4 | 52.6 |
| Avg Volume (50D)Average daily shares traded | 48K | 1.9M | 1.4M | 677K |
Evenly matched — ALKS and INVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
INVA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ALKS as "Buy", ACAD as "Buy", INVA as "Buy". Consensus price targets imply 64.5% upside for INVA (target: $37) vs 10.0% for ALKS (target: $50).
| Metric | NEUPNeuphoria Therape… | ALKSAlkermes plc | ACADACADIA Pharmaceut… | INVAInnoviva, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $49.50 | $33.67 | $37.00 |
| # AnalystsCovering analysts | — | 28 | 37 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | 2 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% | 0.0% | +0.3% |
INVA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
INVA leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). NEUP leads in 1 (Valuation Metrics). 3 tied.
Best OverallInnoviva, Inc. (INVA)Leads 2 of 6 categories
Loading custom metrics...
NEUP vs ALKS vs ACAD vs INVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NEUP or ALKS or ACAD or INVA a better buy right now?
For growth investors, Innoviva, Inc.
(INVA) is the stronger pick with 18. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Innoviva, Inc. (INVA) offers the better valuation at 6. 8x trailing P/E (6. 3x forward), making it the more compelling value choice. Analysts rate Alkermes plc (ALKS) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NEUP or ALKS or ACAD or INVA?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 8x versus Alkermes plc at 31. 5x. On forward P/E, Innoviva, Inc. is actually cheaper at 6. 3x.
03Which is the better long-term investment — NEUP or ALKS or ACAD or INVA?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +84.
2%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: INVA returned +101. 2% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NEUP or ALKS or ACAD or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 03β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately 4454% more volatile than INVA relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NEUP or ALKS or ACAD or INVA?
By revenue growth (latest reported year), Innoviva, Inc.
(INVA) is pulling ahead at 18. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NEUP or ALKS or ACAD or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NEUP or ALKS or ACAD or INVA more undervalued right now?
On forward earnings alone, Innoviva, Inc.
(INVA) trades at 6. 3x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 49. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 64. 5% to $37. 00.
08Which pays a better dividend — NEUP or ALKS or ACAD or INVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is NEUP or ALKS or ACAD or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), +101. 2% 10Y return). Both have compounded well over 10 years (INVA: +101. 2%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NEUP and ALKS and ACAD and INVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NEUP is a small-cap quality compounder stock; ALKS is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.